Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

ABSTRACT:

Background

Immune checkpoint inhibitors have transformed melanoma therapy but frequently cause immune-related adverse events (irAEs), including colitis, that limit treatment. Reliable biomarkers predicting toxicity remain lacking.

Methods

In this retrospective, multicenter study, we analyzed pretreatment serum samples from 331 patients with metastatic melanoma treated with anti-CTLA-4 (ipilimumab), anti-PD-1 (pembrolizumab or nivolumab), or combination ipilimumab/nivolumab. IgG autoantibody reactivity against 832 human protein antigens, including autoimmune targets, cytokines, tumor-associated antigens, and cancer pathway proteins, was profiled using multiplex bead-based arrays. Statistical analysis (Significance Analysis of Microarrays and Cox regression) identified autoant

SUBMITTER: Reschke R 

PROVIDER: S-EPMC12853468 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature